Recent Finacing
Recent Raise
Starton Therapeutics operates a proprietary transdermal delivery platform, developing STAR-LLD (continuous-delivery lenalidomide) and STAR-OLZ (five-day olanzapine adhesive; IND cleared for CINV, entering Phase 2), with industry partners.